A recent early-stage clinical trial sponsored by the National Institute of Allergy and Infectious Diseases (NIAID) found a single injection of a next-generation monoclonal antibody (mAb) treatment candidate was highly protective in adults by neutralizing the parasites in the skin and blood before they can infect liver cells.
L9LS is a laboratory-made version of a naturally occurring mAbs called L9, derived from the blood of a volunteer who had received an investigational malaria vaccine.
-
-
COVID-19 Pandemic Challenges Osteoporosis Management
-
AstraZeneca, J&J Resume U.S. COVID-19 Vaccine Trials
-
Survival From COVID-19 High in Patients With Psoriasis
-
FDA Needs More Safety Data on COVID-19 Vaccines, Experts Say
